Gediminas Jasionis

Hana Biosciences, Inc. (OTC:HNAB) Investors Reevaluate the Stock

by Gediminas Jasionis November 15, 2010

hana_logo.jpgIn the commentary, that came along with the quarterly update, management states the NDA submission for Marqibo compound is currently planned to happen in the first half of 2011. The company is now aiming to submit all 5 modules, that make up the NDA submission, at once and all of them should be prepared by the end of 2010.

Despite the clear timeline and healthy financial position, investors' expectations should be reasonable as share prices might not significantly move up until the NDA submission for Marqibo is truly at hand. Even then, the company will still have to commence Phase III clinical trial, which can disprove the effectiveness of the compound.

Type the characters that you see in the box (5 characters).